UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Dec

    23

    UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

    Read More Share:linkedin| twitter| email

    Dec

    14

    UCB’s Health Equity First Approach to Addressing Population Health Challenges

    Read More Share:linkedin| twitter| email

    Dec

    13

    Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

    Read More Share:linkedin| twitter| email

    Dec

    09

    UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    Dec

    07

    The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

    Read More Share:linkedin| twitter| email

    Dec

    01

    UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)